# Phase 2 Neoadjuvant Doxorubicin and Cyclophosphamide -> Docetaxel With Lapatinib in Stage II/III Her2Neu+ Breast Cancer

> **NCT00404066** · PHASE2 · COMPLETED · sponsor: **George Albert Fisher** · enrollment: 21 (actual)

## Conditions studied

- Breast Cancer
- Metastatic Breast Cancer

## Interventions

- **DRUG:** Lapatinib
- **DRUG:** Doxorubicin
- **DRUG:** Cyclophosphamide
- **DRUG:** Docetaxel
- **DRUG:** Pegfilgrastim
- **DRUG:** Filgrastim
- **DRUG:** Dexamethasone
- **DRUG:** Trastuzumab

## Key facts

- **NCT ID:** NCT00404066
- **Lead sponsor:** George Albert Fisher
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-10
- **Primary completion:** 2010-12
- **Final completion:** 2011-03
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2017-12-22

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00404066

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00404066, "Phase 2 Neoadjuvant Doxorubicin and Cyclophosphamide -> Docetaxel With Lapatinib in Stage II/III Her2Neu+ Breast Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00404066. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*